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tionally, the rapid detection of agricultural pathogens is of
great importance as most emerging infectious diseases are
zoonoses.
doi:10.1016/j.ijid.2008.05.347
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Epidemiologic Evaluation of the Immunity Against Hepati-
tis B in Alexandria, Egypt
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Background: Hepatitis B (HB) vaccine represents one of
the major achievements in the 20th century. The most
important epidemiologic factor affecting the chronic car-
rier rate is age of infection. The earlier in life an infection
occurs, the higher the probability that this infection will
result in chronic carriage.
Methods: A seroepidemiologic study was conducted to
examine the impact of HB vaccination on the carrier state
among a vaccinated group of children (1000) compared to
a non-vaccinated group (500) aged 6 years in Alexandria,
Egypt.
Results: The rate of HbsAg positivity among the vacci-
nated group was found to be 0.8% compared to 2.2% among
the non-vaccinated group. The study showed that the efﬁ-
cacy of HB vaccine in preventing the carriage of HbsAg, 5
years after full course vaccination, was estimated to be
around 67%. However, long-term monitoring should continue
to conﬁrm the efﬁcacy of the vaccine in preventing chronic
carrier state. On the other hand, studying the exposure to
some risk factors associated with hepatitis B virus (HBV)
infection revealed more or less a similar pattern of exposure
among both vaccinated and unvaccinated children.
Conclusion: It can be concluded that the signiﬁcantly
lower rate of HbsAg positivity among the vaccinated com-
pared to the rate among the non-vaccinated is attributed to
the preventive effect of the vaccine.
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Huang
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Background: The plasma-derived hepatitis B virus (HBV)
vaccine has been replaced by recombinant HBV vaccine since
1992 in Taiwan. The duration of immunity conferred by the
recombinant HBV vaccine is unknown. This study aimed to
investigate the long-term protective efﬁcacy of recombinant
HBV vaccine and booster responses in adolescents who had
received recombinant HBV vaccine at their infancy 13—14
years ago.
Methods: In 2007, 835 13- to 14-year-old Taiwanese
healthy middle school students, who had been vaccinated
with recombinant HBV vaccines in infancy in 1993—1994,
were recruited for the screening of HBV seromarkers. The
immune responses to booster HBV vaccines were evaluated
in 573 subjects who were seronegative. A second or third
booster was given following a schedule of 0—1—6 months for
those who remained seronegative after one dose of booster.
Anti-HBs titers were checked 7—10 days after the boosters.
Results: While the HBV vaccine remained highly efﬁ-
cacious in reducing HBsAg positive rate, 71.9% of the
vaccinees had no detectable protective anti-HBs. Following
one booster dose, anti-HBs remained undetectable in 25.9%
(135/522) of subjects with complete 3-doses HBV vaccina-
tion in infancy. A second booster reduced the seronegative
rate to 6.1% (7/115). After the third booster only one subject
(14.3%, 1/7) remained seronegative.
Conclusions: Up to 25.9% percent of adolescents who
were fully vaccinated with recombinant HBV vaccine in their
infancy have lost their immune memory against HBV 13—14
years later. No immediate need of HBV booster was found as
most subjects were well protected at this stage. However,
the decay of immune memory may raise concerns about the
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The purpose of the study was to assess the frequency
and type of adverse events after an inﬂuenza vaccination
in a population of health care workers, consisting of 897
adults in 7 medical centers in Iran, evaluated from October
2006 to February 2007. Fifty-seven percent of the subjects
(513 persons) were male. The mean age of the subjects
was 35.9± 8.1 years (range 19—58). In each medical center,
participants received one dose of the inﬂuenza virus sub-
unit vaccine inactivated with formaldehyde. Subjects were
evaluated 48 hours after their vaccination for symptoms
and signiﬁcant health events for possible adverse events.
Local and systemic reactions were reported by 192 (23.2%)
and 207 (26.1%) persons, respectively. The most common
adverse events to the inﬂuenza vaccine were skin red-
ness (39 cases), in duration (77 cases), pruritus (23 cases)
and pain (181 cases) as local reactions, while fever (84
cases), myalgia (142 cases), headache (94 cases) and weak-
ness (123 cases) were the most common systemic reactions.
Among all the participants, one case of Guillain-barre syn-
drome was reported. A fever of over 38.5 ◦C was found
in 1.4% of the study participants. The adverse reaction
remained more common in women than men after adjust-
ment for other factors (OR = 3.1). Occurrence of systemic
